Personalised to support your treatment decisions
Immunocore has announced trial results showing that overall survival (OS) was statistically significantly improved with IMCgp100 (tebentafusp) compared with investigator’s choice of therapy as treatment of patients with metastatic uveal melanoma in the phase III IMCgp100-202 study (NCT03070392).
Merck has announced the company has submitted applications to the FDA and European Medicines Agency (EMA) for licensure of V 114, Merck’s investigational 15-valent pneumococcal conjugate vaccine, for use in adults 18 years of age and older for prevention of pneumococcal disease.
Liquidia Technologies, Inc., a wholly owned subsidiary of Liquidia Corporation announced that the FDA has issued a complete response letter (CRL) for the company’s New Drug Application (NDA) for LIQ 861 (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH).
You may be interested in ...
The National Advisory Committee on Immunization (NACI) provides the Public Health Agency of Canada (PHAC) with ongoing and timely medical, scientific, and public health advice relating to immunization.
On October 20, 2017, Zoster Vaccine Recombinant, Adjuvanted (Shingrix, GlaxoSmithKline, [GSK] Research Triangle Park, North Carolina), a 2-dose, subunit vaccine containing recombinant glycoprotein E in combination with a novel adjuvant (AS01B), was approved by the Food and Drug Administration for the prevention of herpes zoster in adults aged ≥50 years.
The present guidelines are aimed at residents and board‐certified specialists in the fields of dermatology, ophthalmology, ENT, pediatrics, neurology, virology, infectious diseases, anesthesiology, general medicine and any other medical specialties involved in the management of patients with herpes zoster.